NCT05060640|Unknown
ANAL PRECANCEROUS LESIONS IN HIGH-RISK PATIENTS.
PACCO
PREVALENCE OF ANAL PRECANCEROUS LESIONS IN HIGH-RISK PATIENTS DETECTED BY ROUTINE COLONOSCOPY (PACCO STUDY)
Loading search results
PACCO
PREVALENCE OF ANAL PRECANCEROUS LESIONS IN HIGH-RISK PATIENTS DETECTED BY ROUTINE COLONOSCOPY (PACCO STUDY)
Sponsor study identifier
observational
100
1 country
1
Study Start
August 26, 2021
Actual (reported)Primary Completion
August 31, 2024
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
August 31, 2024
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
HIV-positive patients, women with a history of genital neoplasia and patients under pharmacologically immunosuppression (e.g. transplanted recipients, Crohn´s disease and Lupus) are a high-risk population for anal human-papillomavirus infection and associated complications, like anal precancerous lesions and anal squamous cell carcinoma. There is a lack of information on the prevalence of anal precancerous detected by routine colonoscopy in this population, by evaluating the squamocolumnar junction (the most susceptible area for lesions) during this procedure. Given, the increasing incidence rates of anal squamous cell carcinoma expected for the next two decades and the increase number of at-risk patients, the possible benefit of routine endoscopy in the diagnosis of anal precancerous lesions needs to be further explored.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
August 31, 2024
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
August 26, 2021
Actual (reported)September 17, 2021
Actual (reported)September 29, 2021
Actual (reported)August 31, 2024
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
August 31, 2024
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Prevalence of anal high-grade squamous intraepithelial lesions in the squamocolumnar junction detected during routine colonoscopy.
through study completion, an average of 3 years
Detection of anal HSIL in a routine colonoscopy by using acetic acid and NBI/BLI.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
HIV-positive patients, women with genital neoplasia (cervix, vulva and vagina), solid organ transplanted recipients, patients with inflammatory bowel disease and patients with Lupus.
Fernando Pessoa Teaching Hospital
Gondomar, Porto District, 4420-096, Portugal
First Submitted
September 17, 2021
First Posted
September 29, 2021
Study Start
August 26, 2021
Actual (reported)Primary Completion
August 31, 2024
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Intraoperative HPV Testing Evaluation
Contact the study team to confirm eligibility.
Study Completion
August 31, 2024
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
December 12, 2022
Record last verified: 2022-12
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: